NASDAQ:SCTX Scribe Therapeutics Q2 2026 Earnings Report $29.74 +0.27 (+0.92%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Scribe Therapeutics EPS ResultsActual EPS-$3.84Consensus EPS -$6.20Beat/MissBeat by +$2.36One Year Ago EPSN/AScribe Therapeutics Revenue ResultsActual Revenue$1.92 millionExpected Revenue$3.10 millionBeat/MissMissed by -$1.18 millionYoY Revenue GrowthN/AScribe Therapeutics Announcement DetailsQuarterQ2 2026Date9/2/2026TimeAfter Market ClosesConference Call DateWednesday, September 2, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Scribe Therapeutics Earnings HeadlinesScribe Therapeutics Inc. (NASDAQ:SCTX) Receives $51.75 Average Price Target from AnalystsSeptember 8 at 3:43 AM | americanbankingnews.comEquities Analysts Offer Predictions for SCTX Q3 EarningsSeptember 7, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 11 at 1:00 AM | Chaikin Analytics (Ad)Scribe Reports Narrower Loss In Q2 Due To Lower ExpensesSeptember 3, 2026 | rttnews.comScribe starts phase 1 trial for cholesterol drug STX-1150September 2, 2026 | msn.comScribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsSeptember 2, 2026 | globenewswire.comSee More Scribe Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scribe Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scribe Therapeutics and other key companies, straight to your email. Email Address About Scribe TherapeuticsScribe Therapeutics (NASDAQ:SCTX) is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc. is based in ALAMEDA, Calif.View Scribe Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAeroVironment's Record Backlog and Earnings Beat Fuel Recovery CaseBlock Makes a Federal Trust Bank Move That Could Reshape Its Fintech ModelCould Snowflake's Big Quarter Be a Sign of More to Come? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
